Valuation dashboard for GSK plc (GSK) with P/E 15.26, P/B 4.17, EV/EBITDA 8.62 and dividend yield 3.71%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc.
Analysis Summary
GSK plc reported revenue of 32.67B GBP in the most recent fiscal year, growing at a 5-year CAGR of 6.0%. Net income reached 5.72B GBP, with a -0.1% 5-year CAGR.
Trailing-twelve-month margins: gross margin 73.3%, operating margin 24.1%, net margin 14.5%.
At $48.74 (closing price, October 28, 2026), GSK trades at a P/E of 15.26 and an ROE of 28.35%. Market capitalisation stands at $97.7B, placing it among large-cap names.
Balance sheet quality for GSK: current ratio of 0.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 15.26 |
| Price / Book | 4.17 |
| EV / EBITDA | 8.62 |
| Dividend Yield | 3.71% |
Valuation Models
| DCF Fair Value | $118.27 |
| vs Current Price | +142.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GSK | GSK plc | $97.7B | 15.26 | 4.17 | 28.3% |
| MRK | Merck & Co., Inc. | $348.2B | 112.90 | 8.36 | 6.6% |
| AMGN | Amgen Inc. | $244.3B | 28.08 | 20.77 | 89.3% |
| SNY | Sanofi | $101.2B | 23.69 | 1.34 | 5.5% |
| LLY | Eli Lilly and Company | $1.2T | 43.25 | 33.99 | 92.6% |
| JNJ | Johnson & Johnson | $652.5B | 41.09 | 8.07 | 19.6% |
| AZN | AstraZeneca PLC | $269.2B | 26.06 | 5.23 | 21.7% |
| NVS | Novartis AG | $294.8B | 23.54 | 7.91 | 24.2% |
Price
| Price | $48.74 (closing price, October 28, 2026) |
| Market Cap | $97.7B |
| Exchange | NYSE |
| Country | GB |
Profitability
| Return on Equity | 28.35% |
| Return on Invested Capital | 16.04% |
| Return on Assets | 7.81% |
| Gross Margin | 73.29% |
| Operating Margin | 24.12% |
| Net Margin | 14.52% |
Related companies: MRK · AMGN · SNY · LLY · JNJ · AZN · NVS · NVO
Explore sector: Healthcare · Drug Manufacturers - General
More sections of GSK: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks